Related Experiment Video
Updated: May 6, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Sirolimus conversion may suppress viral replication in hepatitis C virus-positive renal transplant candidates
Amin Soliman1, Ahmed Fathy, Sahier Khashab
1Department of Nephrology, Cairo University, Cairo, Egypt.
Objectives:
Hepatitis C virus in renal transplant recipients is an independent risk factor for sickness and death. It has been shown that one might limit hepatitis C virus progression in liver transplant recipients with sirolimus-based immunosuppression. The mammalian target of rapamycin is an influential molecule for the anti-hepatitis C virus action of interferon. We report our experience with sirolimus conversion in hepatitis C virus-positive patients with chronic allograft nephropathy regarding hepatic and hematologic effects that might affect its future use.
Materials And Methods:
Twenty-five patients who had received renal transplants with anti-hepatitis C virus-positive and normal liver function were enrolled. Ten patients had allograft dysfunction because of cyclosporine nephrotoxicity. Sirolimus was initiated at 2 mg/d and adjusted to 6 to 8 ng/mL. Cyclosporine was gradually tapered and then stopped; 15 patients were used as a control group. Sirolimus-related hepatitis was defined as a rise in liver transferases or alkaline phosphatase or bilirubin over twice the upper limit of normal. Viral replication was defined as elevated liver enzymes and increasing viral load and/or biopsy-proven hepatitis C virus active hepatitis.
Results:
After conversion, there was a reduction of hemoglobin and hematocrit. In 1 patient, the immunosuppressive regimen was changed back to cyclosporine owing to anemia and hepatotoxicity leading to prompt return of hematocrit and liver enzymes to their original values. One of 10 antihepatitis C virus-positive patients (10.0%) developed sirolimus-associated hepatotoxicity, compared with 2 patients in the control group (13%). Sirolimus patients showed a significant decrease in the HCV PCR levels from 700 000 to 400 000 IU/mL; P < .001, compared to 680 000 to 660 000 IU/mL in cyclosporine patients; P = NS, with comparable levels of transaminases
Conclusions:
Our data suggest that sirolimus has the potential to suppress viral replication in hepatitis C virus-positive renal transplant candidates.
Insights
Sirolimus may help suppress Hepatitis C virus (HCV) replication in kidney transplant patients. This study observed reduced viral load in sirolimus-treated patients, with manageable hepatic and hematologic effects.
Area of Science:
- Nephrology
- Hepatology
- Immunology
Background:
- Hepatitis C virus (HCV) is a significant risk factor for morbidity and mortality in renal transplant recipients.
- Sirolimus-based immunosuppression has shown potential in limiting HCV progression in liver transplant recipients.
- The mammalian target of rapamycin pathway is crucial for interferon's anti-HCV activity.
Purpose of the Study:
- To evaluate the hepatic and hematologic effects of sirolimus conversion in HCV-positive renal transplant recipients with chronic allograft nephropathy.
- To assess the impact of sirolimus on viral replication in this patient population.
Main Methods:
- Twenty-five HCV-positive renal transplant recipients with normal liver function were enrolled.
- Ten patients with allograft dysfunction due to cyclosporine nephrotoxicity were switched to sirolimus.
- A control group of 15 patients remained on cyclosporine; sirolimus dosage was adjusted to maintain target levels (6-8 ng/mL).
Main Results:
- Sirolimus conversion led to a significant decrease in HCV RNA levels (P < .001).
- One patient (10%) developed sirolimus-associated hepatotoxicity, requiring a switch back to cyclosporine.
- Comparable transaminase levels were observed between the sirolimus and cyclosporine groups.
Conclusions:
- Sirolimus demonstrates potential in suppressing viral replication in HCV-positive kidney transplant candidates.
- Hepatic and hematologic effects associated with sirolimus require careful monitoring but appear manageable.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Kidney Transplant I: Introduction
Retrovirus Life Cycles
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

